|   In the News

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline


A small Cambridge, Massachusetts-based company is hoping its bet on CNS drugs using a well established pharmaceutical approach — allosteric modulators — will cement its place as a biotech powerhouse in the years to come. Cadent Therapeutics — currently a 9-person team — has already found a partner in Novartis $NVS.

Read more.